|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||10.36 - 10.57|
|52-week range||10.36 - 10.57|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BARCELONA, Spain, January 04, 2023--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023.
BARCELONA, Spain, November 28, 2022--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem. FACILITATE main
BARCELONA, Spain, November 10, 2022--Almirall, S.A. (ALM), the global biopharmaceutical company based in Barcelona, has announced its 9M 2022 financial results.